Amendment 28: DRIVe EZ Broad Agency Announcement

EZBAA-22-100-SOL-00003

Amendment #028

Office of Biomedical Advanced Research and Development Authority Division of Research, Innovation & Ventures (DRIVe)
Easy Broad Agency Announcement EZBAA-22-100-SOL-00003

The purpose of Amendment #028 is the following:

1) Update the closing date for the following Area of
Interest (AOI):

AOI #15: ReDIRECT

2) Update the closing date for the following Area of
Interest (AOI):
AOI #26: Agnostic Diagnostic
3) Reopen the following Area of Interest (AOI):
AOI #17: Digital MCMs

EZBAA-22-100-SOL-00003

Amendment #028

4) Revise the following Area of Interest (AOI):
AOI #17: Digital MCMs

INTRODUCTION AND OVERVIEW INFORMATION

A. Development Opportunity Objective:

Under this Amendment, DRIVe is doing the following:
1)

Updating the closing date for the following research Area of Interest (AOI):

AOI #15: ReDIRECT

2)

Updating the closing date for the following research Area of Interest (AOI): AOI #26: Agnostic Diagnostic

3)

Reopening the following research Area of Interest (AOI): AOI #17: Digital MCMs

4)

Revising the following research Area of Interest (AOI): AOI #17: Digital MCMs

We are now seeking abstract submissions for the following AOI: Digital Medical Countermeasures
BARDA/DRIVe is interested in innovative computational approaches and technologies, such as artificial intelligence (AI), that (1) are the foundation of new medical countermeasures (MCM) for health security threats, or (2) directly support the development or use of MCMs for health security threats. BARDA supports MCMs that diagnose, prevent, or treat injury or illness resulting from chemical, biological, radiological, and nuclear (CBRN) events, including related blast and burn injuries; pandemic influenza; and emerging infectious diseases.
(1) Computational approaches and technologies that are the foundation of new MCMs may include, but are not limited to, algorithms that use data collected with a smartphone or commonly available wearable device to detect or diagnose an injury or illness described above. Proposals must demonstrate that the resulting MCM would be rapidly deployable, inexpensive, simple to use, and equitable.

EZBAA-22-100-SOL-00003

Amendment #028

(2) Computational approaches and technologies that directly support the development or use of MCMs may include, but are not limited to, those that improve triage or clinical workflows for more efficient responses to health security threats, increase MCM accessibility, support multimodal medicine, or evaluate the utility of real-world data or synthetic data for MCM